Dermatology Times asked our readers to share what conferences they are looking forward to in the third quarter of 2024.

Earlier this summer, Meghan Heberton, MD, emphasized the importance and growth of the subspecialty.

Renata Block, MMS, PA-C, interviews fellow colleagues to discuss conference highlights, Psoriasis Awareness Month, community advocacy, and more.

Michele Ramien, MD, discusses biologic therapies for pediatric dermatology, focusing on their impact on vaccines, managing side effects, and tailoring treatment.

Naiem Issa, MD, PhD, shared highlights from his sessions on the 1726 nm laser for acne, atopic dermatitis disease modification, advances in hidradenitis suppurativa, and microneedling techniques for vitiligo.

Dermatology Times asked our readers to share what conferences they are looking forward to in the third quarter of 2024.

Data from a retrospective analysis demonstrated that patients with moderate to severe alopecia areata are at a higher risk of developing atopic dermatitis compared to those with mild alopecia areata.

Linda Stein Gold, MD, reviews data presented at SPD and elaborates on study design, methodology, and results.

Four APPs emphasized the vital role of advanced practice providers in improving patient care and expanding service access.

David Rosmarin, MD, shared his insights on the study in a Q&A with Dermatology Times.

Catch up on coverage from the 2024 Society for Pediatric Dermatology Annual Meeting in Toronto, Ontario, Canada.

The AICHI study found a significant prevalence of severe primary axillary hyperhidrosis in children in Japan, according to a poster presented at the SPD's annual meeting.

Metz and Tollefson share insights on efficient practice management, work-life balance, and exciting developments in pediatric dermatology.

Smidt and Hunt offer insights on navigating pediatric dermatology decision-making, emphasizing learning from clinical scenarios and fostering a culture of feedback and improvement.

Oleogel-10 exhibited potential to alleviate the physical, emotional, and economic strain of dressing changes, according to a poster presented at the SPD's annual meeting.

Catch up on coverage from the third and final day of the 2024 Society for Pediatric Dermatology Annual Meeting in Toronto, Ontario, Canada.

Tapinarof cream 1% has proven to be an effective and safe treatment for atopic dermatitis in diverse populations, according to a poster presented at the SPD's annual meeting.

TMB-001 0.05% demonstrates promising efficacy and safety in treating moderate to severe congenital ichthyosis, according to a poster presented at the SPD's annual meeting.

In this episode, Vikash Oza, MD, and James Treat, MD, discuss their SPD 2024 session (debate) revolving around the topic: Does food trigger eczema?

Browning discusses his participation in an SPD 2024 panel discussion, the future of pediatric dermatology, and more.